氢溴酸泰比培南酯是一种在研的碳青霉烯类口服抗生素。如果获得批准，氢溴酸泰比培南酯将成为美国首个用于治疗复杂尿路感染的口服碳青霉烯类抗生素，为耐药感染提供了一种简单的治疗方法，可以在家中治疗，而不需要在有感染其他传染病风险的医院进行静脉注射治疗。

British pharmaceutical company GSK PLC (GSK) and its Massachusetts-based partner Spero Therapeutics (SPRO) said on Wednesday ...

Drug makers Spero Therapeutics and GSK announced yesterday that a phase 3 trial evaluating their investigational oral ...

GSK plc knew a good thing when it swooped in nearly three years ago to rescue Spero Therapeutics Inc.’s oral antibiotic from a complete response letter (CRL). New pivotal phase III study data showed ...

The government is going to expand import duty exemptions on pharmaceutical raw materials and medical equipment, with 79 new ...

5月28日，美股创新药公司Spero Therapeutics在盘前交易中股价大涨超过220%，一度触发临时停牌。记者发现，股价大幅上涨的驱动因素是，Spero Therapeutics开发的首款口服碳青霉烯类抗生素三期临床取得突破性进展。而这款口服抗生素创新药研发项目此前已获得国际医药巨头葛兰素史克（GSK）青睐，因此其研发进展备受市场瞩目。

A biotech company based out of Massachusetts found a tremendous amount of success mid-week after the company announced that ...

Spero will now have funding to start a new phase 3 trial of the drug – tebipenem pivoxil hydrobromide, to give it its full name – and according to GSK this will be designed based on feedback ...

Get article recommendations from ACS based on references in your Mendeley library. Pair your accounts. Export articles to Mendeley Get article recommendations from ACS based on references in your ...

Ten years later, a biotechnology unit was established. In 1981, the first transdermal delivery system, Scopoderm TTS (hyoscine hydrobromide) was introduced for travel sickness. Ciba-Geigy ...